Mannkind, Game-Chancer in Sachen Diabetik? (Seite 548)
eröffnet am 11.01.11 13:02:26 von
neuester Beitrag 03.04.24 20:06:55 von
neuester Beitrag 03.04.24 20:06:55 von
Beiträge: 6.825
ID: 1.162.683
ID: 1.162.683
Aufrufe heute: 0
Gesamt: 593.803
Gesamt: 593.803
Aktive User: 0
ISIN: US56400P7069 · WKN: A2DMZL · Symbol: MNKD
4,2750
USD
+2,76 %
+0,1150 USD
Letzter Kurs 17:21:10 Nasdaq
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 52,75 | +95,37 | |
| 1,9000 | +59,66 | |
| 6,6600 | +45,73 | |
| 1,3500 | +29,82 | |
| 0,5400 | +28,57 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,4200 | -12,95 | |
| 3,3500 | -15,19 | |
| 0,7603 | -15,56 | |
| 9,6350 | -33,60 | |
| 5,0500 | -35,26 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 47.443.087 von icebox1977 am 06.08.14 11:28:51Hehe ja ich glaub da würde sich jeder freuen, wenn es endlich mal wieder was richtig schönes zu berichten gibt, was den Kurs endlich mal wieder anfeuert! Aber ich glaub die arbeiten da dran und die Geduld zahlt sich bald aus 
Antwort auf Beitrag Nr.: 47.443.045 von Gangal am 06.08.14 11:26:35Ich hoffe (nicht ganz uneigenützig) das Al dir ein richtig fettes Geburtstagspacket schnürt, evtl. springt ja auch was nettes aus der Torte!
Also wenn Mannkind schon so einen Vertrag bis 2019 unterzeichnet für 120 Mio Insulin zu kaufen, dann wird es mit Sicherheit auch einen Vertriebsweg geben, um Affreeza unter die Leute zu bekommen. Somit wird sicherlich auch bald ein Partner kommen, etc. 
Mal sehen was als nächstes an News kommt....da braut sich was zusammen...dieser Bedarf an Insulin schreit nach Mrd. Umsätzen...
http://de.advfn.com/p.php?pid=nmona&article=63159124&xref=ne…
http://www.streetinsider.com/Corporate+News/MannKind+(MNKD)+…
On July 31, 2014, MannKind Corporation (“MannKind”) and Amphastar France Pharmaceuticals S.A.S., a French corporation (“Amphastar”), entered into a Supply Agreement, pursuant to which Amphastar will manufacture for and supply to MannKind certain quantities of recombinant human insulin (“Insulin”) for use in MannKind’s product AFREZZA®. Under the terms of the Supply Agreement, Amphastar will be responsible for manufacturing the Insulin in accordance with MannKind’s specifications and agreed-upon quality standards. MannKind has agreed to purchase annual minimum quantities of Insulin under the Supply Agreement of an aggregate of approximately €120.1 million in calendar years 2015 through 2019. MannKind may request to purchase additional quantities of Insulin over such annual minimum quantities.
Unless earlier terminated, the term of the Supply Agreement expires on December 31, 2019 and can be renewed for additional, successive two year terms upon 12 months written notice, given prior to the end of the initial term or any additional two year term. MannKind and Amphastar each have normal and customary termination rights, including termination for material breach that is not cured within a specific time frame or in the event of liquidation, bankruptcy or insolvency of the other party. In addition, MannKind may terminate the Supply Agreement upon two years’ prior written notice to Amphastar without cause or upon 30 days prior written notice to Amphastar if a controlling regulatory authority withdraws approval for AFREZZA, provided, however, in the event of a termination pursuant to either of the latter two scenarios, the provisions of the Supply Agreement require MannKind to pay the full amount of all unpaid purchase commitments due over the initial term within 60 calendar days of the effective date of such termination.
The foregoing description of the Supply Agreement is only a summary and is qualified in its entirety by reference to the Supply Agreement, a copy of which will be filed as an exhibit to MannKind’s quarterly report on Form 10-Q for the quarter ended September 30, 2014.
http://de.advfn.com/p.php?pid=nmona&article=63159124&xref=ne…
http://www.streetinsider.com/Corporate+News/MannKind+(MNKD)+…
On July 31, 2014, MannKind Corporation (“MannKind”) and Amphastar France Pharmaceuticals S.A.S., a French corporation (“Amphastar”), entered into a Supply Agreement, pursuant to which Amphastar will manufacture for and supply to MannKind certain quantities of recombinant human insulin (“Insulin”) for use in MannKind’s product AFREZZA®. Under the terms of the Supply Agreement, Amphastar will be responsible for manufacturing the Insulin in accordance with MannKind’s specifications and agreed-upon quality standards. MannKind has agreed to purchase annual minimum quantities of Insulin under the Supply Agreement of an aggregate of approximately €120.1 million in calendar years 2015 through 2019. MannKind may request to purchase additional quantities of Insulin over such annual minimum quantities.
Unless earlier terminated, the term of the Supply Agreement expires on December 31, 2019 and can be renewed for additional, successive two year terms upon 12 months written notice, given prior to the end of the initial term or any additional two year term. MannKind and Amphastar each have normal and customary termination rights, including termination for material breach that is not cured within a specific time frame or in the event of liquidation, bankruptcy or insolvency of the other party. In addition, MannKind may terminate the Supply Agreement upon two years’ prior written notice to Amphastar without cause or upon 30 days prior written notice to Amphastar if a controlling regulatory authority withdraws approval for AFREZZA, provided, however, in the event of a termination pursuant to either of the latter two scenarios, the provisions of the Supply Agreement require MannKind to pay the full amount of all unpaid purchase commitments due over the initial term within 60 calendar days of the effective date of such termination.
The foregoing description of the Supply Agreement is only a summary and is qualified in its entirety by reference to the Supply Agreement, a copy of which will be filed as an exhibit to MannKind’s quarterly report on Form 10-Q for the quarter ended September 30, 2014.
Antwort auf Beitrag Nr.: 47.441.365 von Gangal am 06.08.14 09:29:57Aber nachdem ich am 11. August Geburtstag habe, hoffe ich auf ein schönes Geburtstagsgeschenk seitens Mannkind 
Trading Spotlight
VALENCIA, Calif., Aug. 5, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2014 second quarter financial results on Monday, August 11, 2014 and its management will host a conference call to discuss the second quarter financial results and other Company developments at 5:00 PM (Eastern Time) on August 11, 2014.
Die Zahlen interessieren eher nicht - gibt ja noch keinen Umsatz. Wenn hier nichts kommt wg. Partner, etc. dann sehen ich den Kurs eher nach unten gehen! Es muss jetzt endlich mal was passieren hier!
Die Zahlen interessieren eher nicht - gibt ja noch keinen Umsatz. Wenn hier nichts kommt wg. Partner, etc. dann sehen ich den Kurs eher nach unten gehen! Es muss jetzt endlich mal was passieren hier!
MannKind has added a news release to its Investor Relations website.
Title: MannKind Corporation to Hold 2014 Second Quarter Financial Results Conference Call on August 11, 2014
Date(s): 5-Aug-2014 5:00 PM
Title: MannKind Corporation to Hold 2014 Second Quarter Financial Results Conference Call on August 11, 2014
Date(s): 5-Aug-2014 5:00 PM
Wird Zeit, dass hier mal ne Gegenbewegung stattfindet! Ich hoffe es kommen bald mal richtig gute News.
Der Kursrückgang ist temporär, die Weltbörsen brechen ein...aber Mannkind ist und bleibt ein Game-Changer, gute Nachkaufkurse meiner Meinung nach!
Durchsuchen
Mannkind, Game-Chancer in Sachen Diabetik?
